CMS expands carotid stenting coverage to asymptomatic/standard-risk patients; InspireMD supports

InspireMD, Inc.

CMS final NCD extends CAS coverage to asymptomatic and standard-risk patients, expanding addressable market.
InspireMD advancing CAS and TCAR programs in U.S. and E.U. using CGuard EPS stent system.
C-GUARDIANS IDE trial completed enrollment; 30-day safety results at VIVA Nov 1, 2023; PMA filing anticipated H2 2024.
CGuard EPS stent studied in nine clinical trials with >1,850 patients and over 40,000 real-world procedures.
CEO says CMS decision will accelerate shift from open surgery to endovascular 'stent first' approach.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.